Synaptic and plasticity-associated proteins in anterior frontal cortex in severe mental illness

Neuroscience

Volumn 91, Issue 4, 1999, Pages 1247-1255

  Honer, W G ^a   Falkai, P ^b   Chen, C ^a   Arango, V ^c,d   Mann, J J ^c,d   Dwork, A J ^c,d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BONN   (Germany)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Depression; GAP 43; Myelin basic protein; Schizophrenia; Suicide; Synaptophysin

Indexed keywords

MYELIN BASIC PROTEIN; NEUROMODULIN; SYNAPTOPHYSIN;

ARTICLE; BRAIN DEVELOPMENT; BRAIN DYSFUNCTION; CONTROLLED STUDY; DEPRESSION; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MENTAL DISEASE; NERVE CELL PLASTICITY; NERVE REGENERATION; NERVE SPROUTING; NEUROTRANSMISSION; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SCHIZOPHRENIA;

ADULT; AGED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FRONTAL LOBE; GAP-43 PROTEIN; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MENTAL DISORDERS; MIDDLE AGED; MYELIN BASIC PROTEINS; NERVE TISSUE PROTEINS; NEURONAL PLASTICITY; SYNAPSES;

EID: 0032950768     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(98)00679-4     Document Type: Article

References (56)

1. Andreasen N.C. Linking mind and brain in the study of mental illnesses: a project for a scientific psychopathology. Science. 275:1997;1586-1593.
2. Andreasen N.C., Arndt S., Swayze V., Cizadlo T., Flaum M., O'Leary D., Ehrhardt J.C., Yuh W.T.C. Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging. Science. 266:1994;294-298.
3. Benes F.M., Turtle M., Khan Y., Farol P. Myelination of a key relay zone in the hippocampal formation occurs in the human brain during childhood, adolescence, and adulthood. Archs gen. Psychiat. 51:1994;477-484.
4. Benowitz L.I., Perrone-Bizzozero N.I. The expression of GAP-43 in relation to neuronal growth and plasticity: when, where, how, and why? Prog. Brain Res. 89:1991;69-87.
5. Browning M.D., Dudek E.M., Rapier J.L., Leonard S., Freedman R. Significant reductions in synapsin but not synaptophysin specific activity in the brains of some schizophrenics. Biol. Psychiat. 34:1993;529-535.
6. Buchsbaum M.S., Tang C.Y., Peled S., Gudbjartsson H., Lu D., Hazlett E.A., Downhill J., Haznedar M., Fallon J.H., Atlas S.W. MRI white matter diffusion anisotropy and PET metabolic rate in schizophrenia. NeuroReport. 9:1998;425-430.
7. Eastwood S.L., Burnet P.W.J., Harrison P.J. Striatal synaptophysin and haloperidol-induced synaptic plasticity. NeuroReport. 5:1994;677-680.
8. Eastwood S.L., Harrison P.J. Decreased synaptophysin in the medial temporal lobe in schizophrenia demonstrated using immunoautoradiography. Neuroscience. 69:1995;339-343.
9. Eastwood S.L., Harrison P.J. Hippocampal and cortical growth-associated protein-43 messenger RNA in schizophrenia. Neuroscience. 86:1998;437-448.
10. Eastwood S.L., Heffernan J., Harrison P.J. Chronic haloperidol treatment differentially affects the expression of synaptic and neuronal plasticity-associated genes. Molec. Psychiat. 2:1997;322-329.
11. Feinberg I. (1982/83) Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence? J. psychiat. Res. 17, 319-334.
12. Feinberg I. Cortical pruning and the development of schizophrenia. Schizophrenia Bull. 16:1990;567-568.
13. Fog R., Pakkenberg H., Juul P., Bock E., Jørgensen O.S., Andersen J. High-dose treatment of rats with perphenazine. Psychopharmacology. 50:1976;305-307.
14. Gabriel S.M., Haroutunian V., Powchik P., Honer W.G., Davidson M., Davies P., Davis K.L. Increased concentrations of presynaptic proteins in the cingulate cortex of schizophrenics. Archs gen. Psychiat. 54:1997;559-566.
15. Gispen W.H., Leunissen J.L.M., Oestreicher A.B., Verkleij A.J., Zwiers H. Presynaptic localization of B-50 phosphoprotein: the (ACTH)-sensitive protein kinase substrate involved in rat brain polyphosphoinositide metabolism. Brain Res. 328:1985;381-385.
16. Glantz L.A., Lewis D.A. Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia: regional and diagnostic specificity. Archs gen. Psychiat. 54:1997;943-952.
17. Honer W.G., Falkai P., Young C., Wang T., Xie J., Bonner J., Hu L., Boulianne G.L., Lu Z., Trimble W.S. Cingulate cortex synaptic terminal proteins and neural cell adhesion molecule in schizophrenia. Neuroscience. 78:1997;99-110.
18. Honer W.G., Hurwitz T., Li D.K.B., Palmer M., Paty D.W. Temporal lobe involvement in patients with both multiple sclerosis and psychiatric disorders. Archs Neurol. 44:1987;187-190.
19. Honer W.G., Kaufmann C.A., Davies P. Characterization of a synaptic antigen of interest in neuropsychiatric illness. Biol. Psychiat. 31:1992;147-158.
20. Hou X.-E., Lundmark K., Dahlstrom A. SNAP25 and GAP-43 behave differently in decentralized rat superior cervical ganglia. NeuroReport. 8:1997;1051-1056.
21. Hyde T.M., Ziegler J.C., Weinberger D.R. Psychiatric disturbances in metachromatic leukodystrophy: insights into the neurobiology of psychosis. Archs Neurol. 49:1992;401-406.
22. Jernigan T.L., Zisook S., Heaton R.K., Moranville J.T., Hesselink J.R., Braff D.L. Magnetic resonance imaging abnormalities in lenticular nuclei and cerebral cortex in schizophrenia. Archs gen. Psychiat. 48:1991;881-890.
23. Jørgensen O.S. SNAP-25 is the major immunoreactive component of the brain-specific D3 protein. NeuroReport. 7:1995;73-76.
24. Jørgensen O.S., Bolwig T.G. Synaptic proteins after electroconvulsive stimulation. Science. 205:1979;705-707.
25. Jørgensen O.S., Riederer P. Increased synaptic markers in hippocampus of depressed patients. J. neural Transm. 64:1985;55-66.
26. Kapfhammer J.P., Schwab M.E. Inverse patterns of myelination and GAP-43 expression in the adult CNS; neurite growth inhibitors as regulators of neuronal plasticity. J. comp. Neurol. 340:1994;194-206.
27. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
28. Lim K.O., Adalsteinsson E., Spielman D., Sullivan E.V., Rosenbloom M.J., Pfefferbaum A. Proton magnetic resonance spectroscopic imaging of cortical gray and white matter in schizophrenia. Archs gen. Psychiat. 55:1998;346-352.
29. Loessner B., Bullock S., Rose S.P.R. 411B: a monoclonal postsynaptic marker for modulations of synaptic connectivity in the rat brain. J. Neurochem. 51:1988;385-390.
30. Maier N., Ron M.A. Hippocampal age-related changes in schizophrenia: a proton magnetic resonance spectroscopy study. Schizophrenia Res. 22:1996;5-17.
31. Marin C., Tolosa E. Striatal synaptophysin levels are not indicative of dopaminergic supersensitivity. Neuropharmacology. 36:1997;1115-1117.
32. Masliah E., Fagan A.M., Terry R.D., DeTeresa R., Mallory M., Gage F.H. Reactive synaptogenesis assessed by synaptophysin immunoreactivity is associated with GAP-43 in the dentate gyrus of the adult rat. Expl Neurol. 113:1991;131-142.
33. Miyakawa T., Sumiyoshi S., Deshimaru M., Suzuki T., Tomonari H., Yasuoka F., Tatetsu S. Electron microscopic study on schizophrenia: mechanisms of pathological changes. Acta neuropath., Berlin. 20:1972;67-77.
34. Ong W.Y., Garey L.J. Ultrastructural features of biopsied temporopolar cortex (area 38) in a case of schizophrenia. Schizophrenia Res. 10:1993;15-27.
35. Orlovskaya D.D., Denisov D.V., Uranova N.A. The ultrastructural pathology of myelinated fibers and oligodendroglial cells in autopsied caudate nucleus of schizophrenics. Schizophrenia Res. 24:1997;39-40.
36. Pakkenberg B. Total nerve cell number in neocortex in chronic schizophrenics and controls estimated using optical dissectors. Biol. Psychiat. 34:1993;768-772.
37. Patanow C.M., Day J.R., Billingsley M.L. Alterations in hippocampal expression of SNAP-25, GAP-43, stannin and glial fibrillary acidic protein following mechanical and trimethyltin-induced injury in the rat. Neuroscience. 76:1997;187-202.
38. Perrone-Bizzozero N.I., Sower A.C., Bird E.D., Benowitz L.I., Ivins K.J., Neve R.L. Levels of the growth-associated protein GAP-43 are selectively increased in association cortices in schizophrenia. Proc. natn. Acad. Sci. U.S.A. 93:1996;14182-14187.
39. Pujol J., Bello J., Deus J., Martí-Vilalta J.L., Capdevila A. Lesions in the left arcuate fasciculus region and depressive symptoms in multiple sclerosis. Neurology. 49:1997;1105-1110.
40. Ron M.A., Logsdail S.J. Psychiatric morbidity in multiple sclerosis: a clinical and MRI study. Psychol. Med. 19:1989;887-895.
41. Schwab M.E. Molecules inhibiting neurite growth: a minireview. Neurochem. Res. 21:1996;755-761.
42. Selemon L.D., Rajkowska G., Goldman-Rakic P.S. Abnormally high neuronal density in the schizophrenic cortex: a morphometric analysis of prefrontal area 9 and occipital area 17. Archs gen. Psychiat. 52:1995;805-818.
43. Selemon L.D., Rajkowska G., Goldman-Rakic P.S. Elevated neuronal density in prefrontal area 46 in brains from schizophrenic patients: application of a three-dimensional, stereologic counting method. J. comp. Neurol. 392:1998;402-412.
44. Soares J.C., Mann J.J. The anatomy of mood disorders - review of structural neuroimaging studies. Biol. Psychiat. 41:1997;86-106.
45. Stevens J. Abnormal reinnervation as a basis for schizophrenia: a hypothesis. Archs gen. Psychiat. 49:1992;238-243.
46. Szele F.G., Alexander C., Chesselet M.-F. Expression of molecules associated with neuronal plasticity in the striatum after aspiration and thermocoagulatory lesions of the cerebral cortex in adult rats. J. Neurosci. 15:1995;4429-4448.
47. Thompson P.M., Sower A.C., Perrone-Bizzozero N.I. Altered levels of the synaptosomal associated protein SNAP-25 in schizophrenia. Biol. Psychiat. 43:1998;239-243.
48. van Lookeren Campagne M., Oestreicher A.B., van Bergen en Henegouwen P.M.P., Gispen W.H. Ultrastructural double localization of B-50/GAP43 and synaptophysin(p38) in the neonatal and adult rat hippocampus. J. Neurocytol. 19:1990;948-961.
49. Veronesi B., Pringle J., Mezei C. Myelin basic protein-mRNA used to monitor trimethyltin neurotoxicity in rats. Toxicol. appl. Pharmac. 108:1991;428-435.
50. Weickert C.S., Weinberger D.R. A candidate molecule approach to defining developmental pathology in schizophrenia. Schizophrenia Bull. 24:1998;303-316.
51. Weinberger D.R. Schizophrenia: from neuropathology to neurodevelopment. Lancet. 346:1995;552-557.
52. Williamson P., Pelz D., Merskey H., Morrison S., Conlon P. Correlation of negative symptoms in schizophrenia with frontal lobe parameters on magnetic resonance imaging. Br. J. Psychiat. 159:1991;130-134.
53. Williamson P., Pelz D., Merskey H., Morrison S., Karlik S., Drost D., Carr T., Conlon P. Frontal, temporal, and striatal proton relaxation times in schizophrenic patients and normal comparison subjects. Am. J. Psychiat. 149:1992;549-551.
54. Yakovlev P. I. and Lecours A. R. (1967) The myelogenetic cycles of regional maturation of the brain. In Regional Development of the Brain in Early Life (ed. Minkowski A.), pp. 3-70. Blackwell, Oxford.
55. Young C.E., Arima K., Xie J., Hu L., Beach T.G., Falkai P., Honer W.G. SNAP-25 deficit and hippocampal connectivity in schizophrenia. Cerebral Cortex. 8:1998;261-268.
56. Zalcman S. and Endicott J. (1983) Diagnostic Evaluation After Death. Neurosciences Research Branch, National Institute of Mental Health, Washington.